Company profile
REIN THERAPEUTICS, INC.
NASDAQ:RNTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LTI-03 | phase2 | — | 2 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06968845 | phase2 | recruiting | 2026-02-02 | 2027-09-30 | Rein Therapeutics | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis |
| NCT04159831 | phase2 | completed | 2020-09-26 | 2022-03-31 | Rein Therapeutics | A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions |
| NCT05954988 | phase1 | completed | 2023-07-06 | 2024-09-25 | Rein Therapeutics | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients |
| NCT04233814 | phase1 | completed | 2020-01-20 | 2021-12-23 | Rein Therapeutics | Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects |
FDA applications (0)
No records yet.